Market Place
Sourcing Support
Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol
23 Sep 2024 //
BUSINESSWIRE
Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder
01 Apr 2024 //
BUSINESSWIRE
Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
10 Aug 2023 //
PR NEWSWIRE
Vistagen stock soars 1,272% on social anxiety spray data
08 Aug 2023 //
FIERCE BIOTECH
Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol
07 Aug 2023 //
BUSINESSWIRE
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data
01 Jun 2023 //
BUSINESSWIRE
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data
30 May 2023 //
BUSINESSWIRE
Anxiety drugs: stressing the importance of innovation
04 Jun 2018 //
PHARMACEUTICAL JOURNAL
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.